Spartalizumab

5 trials

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

0 Recruiting

4 Completed trials

5 Sponsors

8 Countries

Phase II

Phase I/II

Phase I (Other)

Phase II: 3 Phase I/II: 1 Phase I (Other): 1

Oversight events:

1 temporary halt across 1 trial

View oversight register →

Indications tested

Neoplasm malignant 1

Sponsors using this IMP

Centre Francois Baclesse 1 Centre Hospitalier Universitaire De Bordeaux 1 Centre Hospitalier Universitaire Rouen 1 Novartis Pharma AG 1 Solti Group 1

All trials

5 total

Rollover study for continued safety and tolerability in subjects treated with spartalizumab alone or in combination with other study treatme… Ended

2023-508841-42-00 Phase I (Other) 8 countries Novartis Pharma AG
Spartalizumab and low-dose PAzopanib in Refractory or Relapsed solid TumOrs of pediatric and adults SPARTO Halted

2024-513535-24-00 Phase I/II 1 country Centre Hospitalier Universitaire De Bordeaux
Perioperative Treatment in Resectable Gastric Cancer with Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, … Ended

2024-516299-13-00 Phase II 1 country Centre Francois Baclesse
SPARTANA : Spartalizumab, mDCF (docetaxel, cisplatin and 5-fluorouracil) and radiotherapy in patients with metastatic squamous cell anal car… Ended

2024-516005-23-00 Phase II 1 country Centre Hospitalier Regional Universitaire
Efficacy of antibodies targeting PD1 protein in patients with advanced or metastatic tumors that express high levels of PD1 biomarker. Ended

2023-508549-41-00 Phase II 1 country Solti Group

Showing 1–5 of 5 trials

← All drugs A–Z